High levels of lipoprotein(a) in women associated with increased risk for cardiovascular events
Women with extremely high levels of lipoprotein(a), particularly those with high levels of low-density lipoprotein cholesterol, have an increased risk for cardiovascular events, according to a study in the September 20 issue of JAMA.
Lipoprotein(a) is a specific class of lipoprotein particles found in human plasma, and differs from low-density lipoprotein cholesterol (LDL-C), according to background information in the article. Studies of lipoprotein(a) have shown contrasting results, leading to disagreement about the clinical utility of routinely measuring lipoprotein(a). There is also poor agreement among lipoprotein(a) levels obtained by different tests.
Jacqueline Suk Danik, M.D., M.P.H., of Brigham and Women's Hospital, Boston, and colleagues conducted a study to determine the association of lipoprotein(a) levels with the incidence of future cardiovascular events, such as nonfatal heart attack, nonfatal stroke, coronary revascularization procedures, and cardiovascular-related death. The study included 27,791 initially healthy women in the Women's Health Study, enrolled between November 1992 and July 1995 and followed up for 10 years. Lipoprotein(a) level was measured in blood samples obtained at baseline.
During follow-up, there were 899 new cardiovascular events. In analyses controlling for age, smoking, blood pressure, body mass index, total cholesterol, high-density lipoprotein cholesterol, diabetes, hormone use, C-reactive protein (CRP), and randomization treatment groups, women in the highest quintile of lipoprotein(a) were 1.47 times more likely to develop cardiovascular events than women in the lowest quintile.
"In this large prospective cohort study of initially healthy women, extremely high levels of lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform [a type of protein] size, were associated with increased cardiovascular disease risk, particularly in women with high LDL-C levels. This relationship existed independently of traditional risk markers, and CRP. However, these results were driven almost exclusively by extremely elevated lipoprotein(a) levels among those with above median LDL-C levels, with almost no risk gradient in individuals with lower lipoprotein(a) levels, which constituted the majority of individuals screened," the authors write.
"While [our results are] of pathophysiological interest, we do not believe our data support generalized screening of lipoprotein(a) in the population as a whole because only extremely high levels were associated with cardiovascular risk. … Determination of lipoprotein(a) levels should thus be reserved for high-risk subsets of the population such as individuals with premature [heart attack] who have otherwise normal risk profiles or are at particularly high risk because of circumstances such as familial hypercholesteremia," the researchers write.
(JAMA. 2006;296:1363-1370. Available pre-embargo to the media at www.jamamedia.org.)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Published on PsychCentral.com. All rights reserved.